45 results about "Enterocolitis" patented technology

The present invention provides methods for reducing the incidence of adverse events related to immunotherapy. More specifically, the present invention provides methods for reducing the incidence of enterocolitis associated with anti-CTLA-4 antibody immunotherapy.

The present invention provides a gene chip for quickly detecting pathogens from food source, discloses the preparation method of said gene chip and provides 26 oligonucleotide probe sequences for detection. Said gene chip can quickly, accurately and high-effectively detect and identify the class of the pathogens in food, and its detection range includes staphylococcus aureus, Shiga's bacillus, salmonella, colibacillus 0157, bacillus proteus, mononuclear hyperplastic listerella, enterocolitis yersinia, aeruginous pseudomonads, vibrio parahaemolyticus, vibrio cholerae, bacillus cereus, beta hemolytic streptococcus, coconut fermentation pseudomonads, boticin, vibrio jejuni and bacillus perfringens, etc.

The invention relates to a bovine brucella indirect ELISA antibody detection kit. The kit uses the lipopolysaccharide (LPS) of brucella suis S2 acclimated and induced by the application institution in the 1960s as the coating antigen, and improves the sensitivity of detection. The study improves the LPS purification and purity determination method, and endows the developed kit with good specificity. The kit not only can effectively eliminate the interference of conventional Gram negative bacteria to Brucella, but also can get rid of the technical defect that general brucellosis indirect ELISA (enzyme-linked immunosorbent assay) kits cannot distinguish enterocolitis Yersinia O9 and Escherichia coli O157 interference, and improves the specificity of detection. Through improvement and optimization of the main reagent formula, the reaction background of the kit is effectively controlled, and also the time required by detection is shortened.

The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.

Methods of treating, abating and reducing the risk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include administering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC.

The invention discloses a method for detecting food origin enterocolitis Yersinia by using loop-mediated constant temperature PCR technology, belonging to the food sanitation field. The technical proposal is as follows: enterocolitis Yersinia 16S-23S regions are used as target detection sequences, and four specific primers containing the whole region sequences are designed. The invention comprises extraction of four specific primers of enterocolitis Yersinia 16S-23S regions and food origin enterocolitis Yersinia, detection method for loop-mediated constant temperature PCR amplification and interpretation of results. The method fills the gap of a method for detecting food origin enterocolitis Yersinia by using loop-mediated constant temperature PCR amplification technology, and is used for checking enterocolitis Yersinia in import and export foods. The method has the characteristics of low cost, high efficiency, simple operation and convenience.

The present invention provides a quick and convenient determination method and a determination reagent for acute enterocolitis, which can determine acute enterocolitis quantitatively and objectively.

The I-FABP in collected blood is detected. Preferably, the blood is human blood and I-FABP is human I-FABP, and blood I-FABP is detected by an immunological method. As an immunochemical method, any of an enzyme immunochemical method, a latex agglutination method and an immunochromatography method can be used, and an enzyme immunochemical method is preferably used. More preferably, a sandwich-type enzyme immunoassay is used.

The invention discloses a detection kit for Yersinia rohdei causing enterocolitis. The detection kit comprises primer pairs shown as SEQ ID NO: (1 to 2), SEQ ID NO: (3 to 4) and SEQ ID NO: (5 to 6). The invention further provides a detection method of Yersinia rohdei, the three primer pairs, and application of the primer pairs. The detection kit and the detection method has the advantages that Yersinia rohdei can be detected accurately and effectively; the specificity and the sensitivity are high; the time consumption is low; the detection is fast; fast detection and forecast of water sources and foods can be realized; diseases can be prevented; the economic benefit is improved.

The invention discloses separated endogenous antimicrobial polypeptides and application thereof. The extracted endogenous antimicrobial polypeptides have remarkable antibacterial effect to yersinia enterocolitis, escherichia coli and staphylococcus aureus. Discovered by electron microscope scanning, the separated endogenous antimicrobial polypeptides inhibit bacteria mainly by destroying the integrity of cell membrane of the bacteria and can be utilized to prepare a drug for resisting the yersinia enterocolitis, the escherichia coli and the staphylococcus aureus.

The invention relates to a novel isothermal loop-mediated enterocolitis yersinia nucleic acid label detection reagent, which is characterized in that a front inner primer used in isothermal loop-mediated amplification is labeled with an antigen, meanwhile, a back inner primer used in isothermal loop-mediated amplification is labeled with another antigen, and a gene can be labeled during the amplification of specific target genes of enterocolitis yersinia. After the labeling, a matched colloidal gold strip can be used for fast detecting amplification products of target genes, so the enterocolitis yersinia is detected. The detection reagent provided by the invention has the advantages that the operation is simple and fast, the specificity is high, and the sensitivity is high.

The invention relates to a colloidal gold detection test strip for detecting a Brucella antigen by a sandwich method. The detection test strip is composed of a Brucella antigen detection test strip and a plastic suction head, and the detection test strip is composed of a PVC base plate, a sample pad, a gold label pad, a nitrocellulose membrane and a water absorption pad. A four-strain Brucella monoclonal antibody sandwich method combined with different antigen epitopes is adopted, a colloidal gold labeled Brucella monoclonal antibody 4D7 is coated on a gold label pad, a mixed solution of Brucella monoclonal antibodies 2B5, 5F3 and 6C2 is coated on a detection line, and a goat anti-mouse IgG antibody is coated on a quality control line. The test strip for detecting the Brucella antigen can be used for rapidly detecting bovine breed, sheep breed and swine breed Brucella on site and effectively eliminating interference of enterocolitis yersinia O9 and escherichia coli O157 on Brucella antigen detection. The test strip is high in sensitivity and sensitivity, good in specificity, simple and convenient to use, applicable to detection of samples such as clinical tissues, environments and milk, and also applicable to identification of purely cultured Brucella.

The present invention relates to a novel composition with milk of immunized camelid, particularly, (Camelus dromedarius) as the main component (i.e. active ingredient) and a method for the treatment or prevention of gastrointestinal infections, particularly, infections caused by Escherichia coli (E. coli), Helicobacter Pylori (H. pylori), Campylobacter jejuni (C. jejuni), Salmonella enterica, Shigella dysenteriae, Clostridium perfringens, or Yersinia enterocolitica. Said composition is prepared in the form of pharmaceutical, nutraceutical, or health food preparations. The present invention also discloses a process of preparing said composition.

The use of a polysaccharide in a method for improving the flora of the colon of nursing infants and/or infants, thus treating or preventing colic and enterocolitis and therefore improving and/or generally stimulating the intestinal well-being of nursing infants and/or infants. A food composition for feeding nursing infants and/or infants, including at least one polysaccharide for treating or preventing colic and enterocolitis and improving and/or stimulating the intestinal well-being of nursing infants and/or infants. The polysaccharide used is a branched maltodextrin, preferably with a molecular mass of between 400 and 4500.

The invention discloses a rapid numerical identification method for enterobacteria of food-borne pathogenic bacteria. The rapid numerical identification method includes confirming enterobacteria types and positive probabilities; selecting biochemical reaction required in a numerical method; establishing an enterobacteria database and determining a calculating method in the numerical method; detecting and identifying the bacteria to be detected. The rapid numerical identification method for the enterobacteria of the food-borne pathogenic bacteria has the advantages that pure cultures can be subjected to Gram staining, oxidase and OF experiment in advance, and then the rapid numerical identification method is adopted, so that a satisfactory identification result on the enterobacteria can be obtained; by the rapid numerical identification method, 139 bacteria of 31 categories and 8 unclassified floras, namely 159 classified units in total of enterobacteriaceae can be identified, and Yersinia enterocolitica can be identified to 6 kinds of biochemical types; the rapid numerical identification method is much greater in identified bacteria quantity and much higher in identification accuracy than two existing internationally-recognized similar identification methods on the market.

This invention provides a method of determining risk of necrotizing enterocolitis (NEC) in an infant, comprising the steps of: (a) obtaining a fecal sample of the infant's relevant microbiome; (b) sequencing genetic material in the sample to obtain sequence data for the relevant microbiome; (c) analyzing sequence data for the relevant microbiome to identify biomarkers in the infant's microbiome; and (d) categorizing the NEC risk of the infant using the biomarkers identified in the microbiome of the infant.